Developer docs
API playgroundTry for free, no card

Search company profiles

HistologiX

Full company profile

uuid002ekrl

Namestring
HistologiX
Legal namestring
HistologiX Ltd.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

HistologiX is a privately held Contract Research Organization (CRO) founded in 2005 and headquartered at Biocity Nottingham in the United Kingdom. The company specializes in GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) compliant tissue-based biomarker analysis services for pharmaceutical and biotechnology clients developing novel therapeutics, including cell therapies, therapeutic antibodies, oncolytic viruses, immune oncology antibodies, and RNA modifying enzymes. Its service portfolio comprises six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials) supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation), using techniques including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and digital image analysis on automated platforms.

The company's underlying technology stack centers on automated chromogenic and immunofluorescent assay platforms with an emphasis on standardization and repeatability, complemented by digital pathology capabilities for quantitative tissue data generation. HistologiX differentiates through bespoke project design with tailored project teams (Study Directors, Scientists, Client Account Management) and operates as an extension of client in-house laboratories, with all personnel holding Life Science degrees, Master's, or PhD qualifications. The company is a subsidiary within The Niche CRO Group, and in November 2025 it was awarded ISO 9001:2015 certification by the British Standards Institution for its Quality Management System.

HistologiX generates revenue through professional services contracts, with bespoke project-based pricing and multi-year contract cadence typical of specialized CRO engagements. The company operates a sales-led B2B go-to-market, reaching clients through direct outreach via its Client Solutions Team, active presence at industry conferences (BioTrinity, Bionow Oncology, Biomarkers and Precision Medicine), and a social media presence on LinkedIn, Facebook, Twitter, and Instagram. Pricing is quote-based and not publicly disclosed, consistent with a high-touch, relationship-driven niche CRO model rather than a transactional or platform-based offering. The company co-founder Andrew Lawrence passed away in summer 2023.

Short descriptiontext

HistologiX is a UK-based, GLP/GCP compliant contract research organization specializing in tissue-based biomarker analysis, including histology, IHC, immunofluorescence, in situ hybridization, and digital pathology, serving pharmaceutical and biotechnology clients developing novel therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, tissue biomarker analysis, histopathology services, immunohistochemistry assays, digital pathology services
Industry1 code
PRIMARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Bespoke tissue-based biomarker analysis services provided to pharmaceutical and biotech companies under GLP/GCP compliance. Services include histology, immunohistochemistry, immunofluorescence, in situ hybridization, and digital image analysis. Revenue is generated through project-based contracts with tailored project teams including Study Directors, Scientists, and Client Account Management.

histologix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Bespoke project-based pricing tailored to individual client requirements and study specifications.
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

histologix.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) providing specialist tissue-based biomarker analysis services to pharmaceutical and biotechnology companies. Core offerings include histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis across the drug development continuum from discovery through clinical phases, with emphasis on bespoke, tailored project engagements.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) offering a unified portfolio of tissue-based biomarker analysis services. The company provides six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials), supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation). Services span from sample collection and logistics through to data analysis, incorporating techniques including IHC (immunohistochemistry), IF (immunofluorescence), ISH (in situ hybridisation), and digital image analysis. The company also offers specialized toxicology study support and works with cutting-edge therapeutics including cell therapies, oncolytic viruses, and RNA modifying enzymes.

Product and service7 records
1Histology
CategoryCRO Service
Description

Specialised staining methods and histological tissue preparation services supporting toxicology studies and pre-clinical research for pharmaceutical and biotech clients.

2Supporting Toxicology Studies
CategoryCRO Service
Description

Toxicology study support services including picrosirius red staining for collagen fiber assessment to evaluate tissue damage and response in pre-clinical safety studies.

3Cellular Pathology
CategoryCRO Service
Description

Cellular pathology services providing analysis and characterisation of cellular samples for drug development research.

4Digital Pathology
CategoryCRO Service
Description

Digital pathology and image analysis services delivering quantitative data generation from tissue samples using immunohistochemistry and digital pathology techniques.

5Immuno-oncology
CategoryCRO Service
Description

Immuno-oncology testing services supporting the development of immune oncology therapeutic antibodies and related therapeutics through tissue-based analysis.

6Tissue Cross-Reactivity
CategoryCRO Service
Description

Tissue cross-reactivity studies for safety assessment of therapeutic antibodies, supporting regulatory submissions and pre-clinical development.

7Clinical Trials
CategoryCRO Service
Description

GCP compliant clinical trial support services for tissue-based biomarker analysis across clinical phase studies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1The Niche CRO Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HistologiX is part of The Niche CRO Group, an umbrella organization providing strategic alignment and shared resources across specialized CRO services in the life sciences sector. This affiliation provides organizational scale and credibility within the contract research industry.

histologix.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CellCarta is a specialized CRO focused on histopathology, immunohistochemistry, digital pathology, and tissue-based biomarker analysis for pharma and biotech, very similar in scope to HistologiX. Both serve pre-clinical and clinical trial work with GLP/GCP-aligned capabilities.

TypeBroad incumbent
Description

ICON is one of the world's largest CROs offering clinical research, bioanalytical, and central lab services, including histology and biomarker capabilities, competing with HistologiX for global clinical trial support work.

3Histo-Scientific Research Laboratories (HSRL)
TypeDirect peer
Description

HSRL is a GLP-compliant histology and pathology CRO providing IHC, ISH, and tissue-based services to pharma and biotech, directly comparable to HistologiX's pre-clinical histology and toxicology support offerings.

TypeBroad incumbent
Description

Labcorp Drug Development is a global CRO with central laboratory and anatomic pathology services that overlaps HistologiX's clinical trial tissue analysis, though it competes as a full-service incumbent rather than a specialist.

TypeDirect peer
Description

Flagship Biosciences is a digital pathology CRO specializing in tissue-based biomarker quantification and IHC image analysis for pharmaceutical clients, directly overlapping HistologiX's digital pathology and immuno-oncology services.

TypeDirect peer
Description

QualTek is a specialty IHC and molecular pathology CRO providing tissue-based biomarker analysis for immuno-oncology and drug development, closely mirroring HistologiX's niche focus on therapeutic antibody characterization and IHC.

TypeBroad incumbent
Description

Charles River is a global full-service CRO offering preclinical research, safety assessment, and discovery services that includes histopathology and tissue-based biomarker capabilities as part of a much broader portfolio, competing with HistologiX for outsourced histopathology work.

TypeDirect peer
Description

Propath is a UK-based specialist histology and IHC service provider serving pharma and biotech, offering comparable GLP-compliant tissue-based biomarker and digital pathology services to HistologiX in a similar UK/European market.

TypeBroad incumbent
Description

NeoGenomics operates a specialty oncology-focused clinical laboratory with extensive IHC and molecular pathology capabilities, providing a broader-scale alternative for tissue-based biomarker services that competes with HistologiX in the oncology testing space.

TypeDirect peer
Description

Mosaic Laboratories is an anatomic and clinical pathology CRO offering IHC, ISH, and tissue-based biomarker services to pharma/biotech sponsors, making it a direct competitor to HistologiX in the GLP-compliant histology niche.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HistologiX

Contract Research Organization (CRO) Serviceshistologix.co.uk

HistologiX is a UK-based, GLP/GCP compliant contract research organization specializing in tissue-based biomarker analysis, including histology, IHC, immunofluorescence, in situ hybridization, and digital pathology, serving pharmaceutical and biotechnology clients developing novel therapeutics.

What HistologiX does

HistologiX is a privately held Contract Research Organization (CRO) founded in 2005 and headquartered at Biocity Nottingham in the United Kingdom. The company specializes in GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) compliant tissue-based biomarker analysis services for pharmaceutical and biotechnology clients developing novel therapeutics, including cell therapies, therapeutic antibodies, oncolytic viruses, immune oncology antibodies, and RNA modifying enzymes. Its service portfolio comprises six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials) supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation), using techniques including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and digital image analysis on automated platforms.

The company's underlying technology stack centers on automated chromogenic and immunofluorescent assay platforms with an emphasis on standardization and repeatability, complemented by digital pathology capabilities for quantitative tissue data generation. HistologiX differentiates through bespoke project design with tailored project teams (Study Directors, Scientists, Client Account Management) and operates as an extension of client in-house laboratories, with all personnel holding Life Science degrees, Master's, or PhD qualifications. The company is a subsidiary within The Niche CRO Group, and in November 2025 it was awarded ISO 9001:2015 certification by the British Standards Institution for its Quality Management System.

HistologiX generates revenue through professional services contracts, with bespoke project-based pricing and multi-year contract cadence typical of specialized CRO engagements. The company operates a sales-led B2B go-to-market, reaching clients through direct outreach via its Client Solutions Team, active presence at industry conferences (BioTrinity, Bionow Oncology, Biomarkers and Precision Medicine), and a social media presence on LinkedIn, Facebook, Twitter, and Instagram. Pricing is quote-based and not publicly disclosed, consistent with a high-touch, relationship-driven niche CRO model rather than a transactional or platform-based offering. The company co-founder Andrew Lawrence passed away in summer 2023.

HistologiX firmographics

Firmographics
Name
HistologiX
Legal name
HistologiX Ltd.
Website
https://histologix.co.uk
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
HistologiX is a UK-based, GLP/GCP compliant contract research organization specializing in tissue-based biomarker analysis, including histology, IHC, immunofluorescence, in situ hybridization, and digital pathology, serving pharmaceutical and biotechnology clients developing novel therapeutics.
Ownership category
akta.pro rank

HistologiX industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Contract research services
  • Tissue biomarker analysis
  • Histopathology services
  • Immunohistochemistry assays
  • Digital pathology services

Where HistologiX is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

HistologiX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Bespoke tissue-based biomarker analysis services provided to pharmaceutical and biotech companies under GLP/GCP compliance. Services include histology, immunohistochemistry, immunofluorescence, in situ hybridization, and digital image analysis. Revenue is generated through project-based contracts with tailored project teams including Study Directors, Scientists, and Client Account Management.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractBespoke project-based pricing tailored to individual client requirements and study specifications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

HistologiX product offering

Product offering

Core offering

HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) providing specialist tissue-based biomarker analysis services to pharmaceutical and biotechnology companies. Core offerings include histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis across the drug development continuum from discovery through clinical phases, with emphasis on bespoke, tailored project engagements.

Product overview

HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) offering a unified portfolio of tissue-based biomarker analysis services. The company provides six core service lines (Histology, Cellular Pathology, Digital Pathology, Immuno-oncology, Tissue Cross-Reactivity, and Clinical Trials), supported by three expertise areas (Cell and Tissue Analysis, Biomarker Investigation, and Therapeutic Antibody Characterisation). Services span from sample collection and logistics through to data analysis, incorporating techniques including IHC (immunohistochemistry), IF (immunofluorescence), ISH (in situ hybridisation), and digital image analysis. The company also offers specialized toxicology study support and works with cutting-edge therapeutics including cell therapies, oncolytic viruses, and RNA modifying enzymes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Histology Specialised staining methods and histological tissue preparation services supporting toxicology studies and pre-clinical research for pharmaceutical and biotech clients.
  • Supporting Toxicology Studies Toxicology study support services including picrosirius red staining for collagen fiber assessment to evaluate tissue damage and response in pre-clinical safety studies.
  • Cellular Pathology Cellular pathology services providing analysis and characterisation of cellular samples for drug development research.
  • Digital Pathology Digital pathology and image analysis services delivering quantitative data generation from tissue samples using immunohistochemistry and digital pathology techniques.
  • Immuno-oncology Immuno-oncology testing services supporting the development of immune oncology therapeutic antibodies and related therapeutics through tissue-based analysis.
  • Tissue Cross-Reactivity Tissue cross-reactivity studies for safety assessment of therapeutic antibodies, supporting regulatory submissions and pre-clinical development.
  • Clinical Trials GCP compliant clinical trial support services for tissue-based biomarker analysis across clinical phase studies.

Companies that use HistologiX

Customer profile

Segments2 records

Ideal customer profiles2 records

HistologiX technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

HistologiX partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • The Niche CRO GroupcoreStrategic or Co-development PartnerHistologiX is part of The Niche CRO Group, an umbrella organization providing strategic alignment and shared resources across specialized CRO services in the life sciences sector. This affiliation provides organizational scale and credibility within the contract research industry.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

HistologiX competitors and assessment

Company assessment

Direct peers

  • CellCarta (formerly HistoGeneX): CellCarta is a specialized CRO focused on histopathology, immunohistochemistry, digital pathology, and tissue-based biomarker analysis for pharma and biotech, very similar in scope to HistologiX. Both serve pre-clinical and clinical trial work with GLP/GCP-aligned capabilities.
  • Histo-Scientific Research Laboratories (HSRL): HSRL is a GLP-compliant histology and pathology CRO providing IHC, ISH, and tissue-based services to pharma and biotech, directly comparable to HistologiX's pre-clinical histology and toxicology support offerings.
  • Flagship Biosciences: Flagship Biosciences is a digital pathology CRO specializing in tissue-based biomarker quantification and IHC image analysis for pharmaceutical clients, directly overlapping HistologiX's digital pathology and immuno-oncology services.
  • QualTek Molecular Laboratories: QualTek is a specialty IHC and molecular pathology CRO providing tissue-based biomarker analysis for immuno-oncology and drug development, closely mirroring HistologiX's niche focus on therapeutic antibody characterization and IHC.
  • Propath UK: Propath is a UK-based specialist histology and IHC service provider serving pharma and biotech, offering comparable GLP-compliant tissue-based biomarker and digital pathology services to HistologiX in a similar UK/European market.
  • Mosaic Laboratories: Mosaic Laboratories is an anatomic and clinical pathology CRO offering IHC, ISH, and tissue-based biomarker services to pharma/biotech sponsors, making it a direct competitor to HistologiX in the GLP-compliant histology niche.

Broad incumbents

  • ICON plc: ICON is one of the world's largest CROs offering clinical research, bioanalytical, and central lab services, including histology and biomarker capabilities, competing with HistologiX for global clinical trial support work.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a global CRO with central laboratory and anatomic pathology services that overlaps HistologiX's clinical trial tissue analysis, though it competes as a full-service incumbent rather than a specialist.
  • Charles River Laboratories: Charles River is a global full-service CRO offering preclinical research, safety assessment, and discovery services that includes histopathology and tissue-based biomarker capabilities as part of a much broader portfolio, competing with HistologiX for outsourced histopathology work.
  • NeoGenomics: NeoGenomics operates a specialty oncology-focused clinical laboratory with extensive IHC and molecular pathology capabilities, providing a broader-scale alternative for tissue-based biomarker services that competes with HistologiX in the oncology testing space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

HistologiX social profiles

Digital presence

HistologiX compliance and trust

Trust signal

Compliance3 records

HistologiX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HistologiX leadership team

Management profile

Number of profiles

Profiles1 record

HistologiX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HistologiX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HistologiX

What does HistologiX do?

HistologiX is a GLP and GCP compliant Contract Research Organisation (CRO) providing specialist tissue-based biomarker analysis services to pharmaceutical and biotechnology companies. Core offerings include histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridisation (ISH), and digital image analysis across the drug development continuum from discovery through clinical phases, with emphasis on bespoke, tailored project engagements.

Is HistologiX a public or private company?

HistologiX is a private company. It is classified as corporate owned and is currently operating.

When was HistologiX founded?

HistologiX was founded in 2005. It employs 11 to 50 people.

Where is HistologiX based?

HistologiX is headquartered in Nottingham, United Kingdom, in the Europe region.

How does HistologiX make money?

One revenue line is on record: contract Research Services.

Who are HistologiX's main competitors?

Direct peers on record are CellCarta (formerly HistoGeneX), Histo-Scientific Research Laboratories (HSRL), Flagship Biosciences, QualTek Molecular Laboratories, Propath UK and Mosaic Laboratories. Broad incumbents are ICON plc, Labcorp Drug Development (formerly Covance), Charles River Laboratories and NeoGenomics.

Does HistologiX have an API?

No public API is recorded for HistologiX.

What industry is HistologiX in?

HistologiX's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales